Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Falk Steffen

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Stroke|September 21, 2019
NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic StrokeTimo Uphaus, Stefan Bittner, Sonja Gröschel, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 21, 2022
Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal CohortFalk Steffen, Timo Uphaus, Nina Ripfel, et al.
Therapeutic Advances in Neurological Disorders|October 28, 2021
Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosusSinah Engel, Simone Boedecker, Paul Marczynski, et al.
Annals of Clinical and Translational Neurology|September 25, 2023
Strict blood pressure control following thrombectomy is associated with neuronal injury and poor functional outcomeMarianne Hahn, Eyad Hayani, Lynn Bitar, et al.
Multiple Sclerosis and Related Disorders|May 3, 2024
Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosisKimberly Koerbel, Michelle Maiworm, Martin Schaller-Paule, et al.
European Journal of Neurology|May 15, 2023
Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: Results from the REDUCE-GAD trialJan Hendrik Schaefer, Martin A Schaller-Paule, Katharina Wenger, et al.
Frontiers in Immunology|February 17, 2025
Biomarker combinations from different modalities predict early disability accumulation in multiple sclerosisVinzenz Fleischer, Tobias Brummer, Muthuraman Muthuraman, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosisCaspar B Seitz, Falk Steffen, Muthuraman Muthuraman, et al.
European Journal of Neurology|January 8, 2024
Studying serum neurofilament light chain levels as a potential new biomarker for small fiber neuropathyPanoraia Baka, Livia Steenken, Fabiola Escolano-Lozano, et al.
European Journal of Radiology|August 7, 2023
Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosisKatharina J Wenger, Maya C Hoelter, Yavor Yalachkov, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Stroke|September 21, 2019
NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic StrokeTimo Uphaus, Stefan Bittner, Sonja Gröschel, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 21, 2022
Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal CohortFalk Steffen, Timo Uphaus, Nina Ripfel, et al.
Therapeutic Advances in Neurological Disorders|October 28, 2021
Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosusSinah Engel, Simone Boedecker, Paul Marczynski, et al.
Annals of Clinical and Translational Neurology|September 25, 2023
Strict blood pressure control following thrombectomy is associated with neuronal injury and poor functional outcomeMarianne Hahn, Eyad Hayani, Lynn Bitar, et al.
Multiple Sclerosis and Related Disorders|May 3, 2024
Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosisKimberly Koerbel, Michelle Maiworm, Martin Schaller-Paule, et al.
European Journal of Neurology|May 15, 2023
Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: Results from the REDUCE-GAD trialJan Hendrik Schaefer, Martin A Schaller-Paule, Katharina Wenger, et al.
Frontiers in Immunology|February 17, 2025
Biomarker combinations from different modalities predict early disability accumulation in multiple sclerosisVinzenz Fleischer, Tobias Brummer, Muthuraman Muthuraman, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosisCaspar B Seitz, Falk Steffen, Muthuraman Muthuraman, et al.
European Journal of Neurology|January 8, 2024
Studying serum neurofilament light chain levels as a potential new biomarker for small fiber neuropathyPanoraia Baka, Livia Steenken, Fabiola Escolano-Lozano, et al.
European Journal of Radiology|August 7, 2023
Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosisKatharina J Wenger, Maya C Hoelter, Yavor Yalachkov, et al.
Pageof 6